{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 28 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '5.', 'ASSESSMENTS', '5.1', 'ASSESSMENT OF EFFICACY', '5.1.1', 'Endpoints of efficacy', '5.1.1.1', 'Primary endpoint', 'Change from baseline in 6MWD at 12 weeks', '5.1.1.2', 'Secondary endpoints', 'Change from baseline in QoL (SGRQ, KBILD, UCSD SOBQ) at 12 and 24', 'weeks', 'Change from baseline in 6MWD at 24 weeks', 'Change from baseline in lung function (FVC) at 12 weeks and 24 weeks using', 'each of', 'Absolute change from baseline of FVC and FVC % predicted', 'Relative change from baseline of FVC and FVC % predicted', 'Absolute categorical change of FVC % predicted up to 12 and 24', 'weeks: decrease by >5%, increase by >5%, and change within VI 5', 'Absolute categorical change of FVC% predicted up to 12 and 24', 'weeks: decrease by >10, increase by >10, and change within 10', 'Change from baseline in daily accelerometer activity from baseline at 12 and', '24 weeks', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 29 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '5.1.2', 'Assessment of efficacy', '5.1.2.1', '6 Minute walk test', 'The distance measured in the 6 Minute Walk Test at 12 and 24 weeks will be assessed', 'according to the procedures described in Appendix 10.1.', 'Four 6 MWTs will be performed during the trial (one practice and three tests). At Visit 1', 'a', 'practice 6 MWT, also referred to as the Titration Walk Test, will be conducted to acquaint the', 'patient with the procedure and to determine the level of oxygen needed for subsequent', 'testing. As per inclusion criterion #8, patients must be physically able to perform a 6MWT,', 'as per the instructions. Patients who cannot complete the Titration Walk Test will be', 'considered a Screen Failure. Three 6 MWTs will be conducted during the randomized', 'treatment phase at Visits 2 (baseline), 5 and 7 (End of Treatment). During the 6 MWT,', 'the', 'Borg Scale will be administered. Detailed instructions for the conduct of the 6 MWT and', 'Borg Scale are provided in the ISF and Appendix 10.1 and 10.2 and in the distributed', 'instructional video. It is important the instructions are followed exactly. The test will be', 'performed at approximately the same time each day from time of Visit 2 testing. Patients', 'who cannot complete the 6MWT after randomization will remain in the trial.', '5.1.2.2', 'Change in quality of life', 'Change from baseline in QoL will be measured using the SGRQ, KBILD, and UCSD-SOBQ', 'questionnaires at 12 and 24 weeks. The questionnaires are described in Appendix 10.3, 10.5', 'and 10.6. The questionnaires should be completed first during the study visit, prior to', 'pulmonary function testing and other procedures. The questionnaires will be completed at', 'Visits 1, 2, 5 and 7.', '5.1.2.3', 'Assessment of lung function', 'Lung function will be assessed at all visits using standard spirometry, using equipment', 'provided at the study site and the NHANES equation (or equivalent after discussion with', 'Clinical Monitor). Spirometry measurements must be performed according to ATS/ERS 2005', 'guideline (P05-12782), including daily calibration of the spirometer, and regular calibration', 'of the calibration pump. Spirometry will be conducted while the patient is in a seated', 'position. The test will be done in triplicate (three curves to be provided), and the best result', 'selected according to the guidelines. The best of three efforts will be defined as the highest', 'FVC, obtained on any of the three blows meeting the ATS/ERS criteria with preferably a', 'maximum of five manoeuvres.', 'Efforts should be made, to schedule the spirometric measurements at approximately the same', 'time of the day, with reference to baseline measurement (Visit 2). On days of clinic visits,', 'patients must refrain from strenuous activity at least 12 hours prior to pulmonary function', 'testing. Smoking should be discouraged throughout the visit days (clinic visit) and will not be', 'permitted in the 30-minute period prior to spirometry. Patients should also avoid cold', 'temperatures, environmental smoke, dust, or areas with strong odours (e.g. perfumes). If', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}